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INTRODUCTION
Enolase (2-phospho-D-glycerate hydrolase) is a glycolytic
enzyme expressed by several isoenzymatic dimmers (,
, , , ) composed of three distinct subunits (, ,
). It was first described by Moore and McGregor in
1965. The -subunit is widely distributed in mammalian
tissues and glial cells of the brain, while the -subunit is
localised primarily in the skeletal muscle and the myocar-
dial tissue. Three different isoenzymes have been found in
human brain: ,  and , with a molecular weight
of approximately 80,000 daltons each. The  and 
isoforms are known as neuron specific enolase (NSE)
because they initially were found in neurons and neuroen-
docrine cells. The -isoenzyme is also a dimmer and was
designated as non-neuronal enolase. There are distin-
guished differences in biochemical properties between
these two isoforms from brain tissue; most important 
of these differences is apparently the complete lack of
immunological cross reactivity, which has been used for
the quantification of NSE by several immunoassays.
NSE’s isoelectric point is 4.7 and is characterised by chlo-
ride, urea and temperature stability. It is assumed that
NSE, being an enzyme from the cellular cytoplasm, is
released during cell destruction. Thus, its presence in the
British Journal of Anaesthetic & Recovery Nursing Vol. 9 No. 1 © Cambridge University Press, 2008
Neuron Specific Enolase (NSE): A Valuable 
Prognostic Factor of Central Nervous System 
Dysfunction Following Cardiac Surgery
E.A. Konstantinou, K. Venetsanou, A.P. Mitsos, K.V. Mamoura, 
E.E. Theodosopoulou, T. Fotis, G. Baltopoulos
Evgenidion University Hospital, National and Kapodistrian University of Athens, 
Faculty of Nursing, Athens, Greece 
Original Article
British Journal of Anaesthetic & Recovery Nursing
Vol. 9(1), 22–28
doi:10.1017/S1742645608000132
© Cambridge University Press, 2008
ABSTRACT
Purpose: The aim of this study was to evaluate
neuron specific enolase (NSE) as prognostic
factor for CNS disorders developed in relation
to cardiac surgery.
Patients and methods: A cohort of 92 patients
were divided into two groups; the experimental
group consisted of patients undergoing open-
heart bypass surgery (50 patients) and the con-
trol group consisting of 42 patients undergoing
general surgery procedures. The blood levels of
NSE were measured in both groups before and
24 h after the operation and have been related
to the incidence of the postoperative brain
damage as well as to the duration of the extra-
corporeal circulation (ECC).
Results: The analysis of our results showed that
the changes of blood NSE levels, before and
immediately after ECC in open-heart surgery
have been related to the incidence of post-
operative brain dysfunction according to a spe-
cific mathematical equation. This incidence was
raised also in relation to the age of the patient and
the duration of ECC. On the contrary, NSE seems
to have no prognostic value in general surgery.
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Conclusion: NSE can be used in cardiac surgery
as a simple and reliable prognostic factor to
predict postoperative brain dysfunction.
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circulation is related to a high death rate of cells with neu-
roendocrine differentiation, a characteristic of tumours
producing the enzyme [Zomzely-Neurath, 1983]. This
specific identification of NSE in blood has been exten-
sively used to detect small cell lung cancer, neuroblastoma
[Massaron et al, 1998; Zeltzer et al, 1986], neuroen-
docrine tumours [Ishguro et al, 1983], Creutzfeldt-Jacob
disease [Zerri et al, 1995], malignant melanoma [Lorenz
et al, 1989], seminoma [Fossa et al, 1992], Merkel cell
carcinoma [Chang et al, 1998], medulloblastoma [Zeltzer
et al, 1986], retinoblastoma [Ke Ping et al, 1995] 
and Guillain Barre syndrome [Mokuno et al, 1992].
According to Kirino et al, NSE seems to be a marker of
neuronal regeneration [Kirino et al, 1983].
NSE is also released from the brain to cerebrospinal
fluid (CSF), as a result of an acute brain injury. Brain
damage in patients undergoing open-heart surgery can
result from brain ischaemia due to emboli (either air or
thrombus) sent to the brain circulation through the ECC
pump [McKibbin et al, 1976]. Embolic events caused by
little pieces of plastic have been frequently reported in the
past but currently, air, platelets thrombus and ECC agents
are now considered as the commonest embolisation fac-
tors [Pearson et al, 1984]. It seems that the reduction of
body temperature during ECC and the administration of
barbiturates minimises the brain requirements for oxygen
and protects it from the ischaemia that the emboli may
cause [Steen et al, 1983]. Other drugs such as Ca
blockers, 2-chloroadenosine [Evans et al, 1987] and
phenytoin [Artru and Michenfelder, 1980] have also been
used to reduce the incidence of postoperative brain dam-
age following open-heart surgery. Among this neuropro-
tection process, it is very important to be able to identify
in advance the patients in high-risk to develop brain dys-
function postoperatively. A large number of different
agents and biomarkers have been occasionally used for
the prognosis of postoperative brain damage during 
cardiac surgery. The S100 protein [Sellman et al, 1992],
AK [Aberg et al, 1984], CK-BB [Taylor et al, 1980] are
some of them used with moderate results.
METHODS
Our double blind study was based on a database of 
100 patients admitted in two different departments; 50
of them in a Cardiac Surgery Department scheduled 
for open-heart surgery and 50 in a General Surgery
Department for general surgery procedures respectively.
The study protocol has been approved by the University’s
Scientific Ethics Committee. All patients were able to
communicate with the investigators before the operation
and an informed consent has been obtained in all cases.
All of them had a previously unremarkable neurological
and medical history upon their admission. The study was
designed to measure and compare the level of NSE vari-
ance in the body serum of the patients before and after
their scheduled operation. Thus, this patient population
has been divided in two groups: The first group (group A),
composed of 50 patients undergoing cardiac surgery
because of coronary heart disease, and the second group
(group B), composed of 50 patients also undergoing 
general surgery procedures. Among these two groups, we
studied the correlation between the variance of the levels
of NSE and the incidence of postoperative brain damage
measured by the Hasegawa scale.
In order to measure NSE, we collected four blood
samples (3 mL) at the following periods:
Group A:
– Sample 1: 24 h before the induction to anaesthesia
– Sample 2: before the entrance in the ECC
– Sample 3: immediately after the ECC
– Sample 4: 24 h after the operation.
Group B:
– Sample 1: 24 h before the induction to anaesthesia
– Sample 2: in the middle of the operation
– Sample 3: at the end of the operation
– Sample 4: 24 h after the operation.
The above blood samples were immediately centrifuged
and the serum was frozen at 70°C and stored for later
NSE analysis, using a commercially available immuno-
radiometric assay kit. The anaesthetic drug protocol in
both groups included the following agents: midazolam,
vekouronioum, fentanyl, propofol and isoforenium, in
doses depended on the body weight of the patients.
RESULTS
The final study included 92 patients (33 men and 59
women). 42 of them had undergone general surgery 
and 50 cardiac surgery. Eight patients were excluded
from the study either because one of the blood samples
was inappropriate or because the patient was unable 
or unwilling to be evaluated with the Hasegawa score
postoperatively. The mean age was 61.7  11.6 years
(mean  sd) and the time of stress period was 67  53.7
min. The large standard deviation was due to the large
sample range. The smallest recorded value was 2 min
and the largest 314 min. For each case, the level of NSE
has been recorded four times. The first NSE level
recorded 24 h before surgery, the second level just
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before surgery, the third immediately after surgery and
the fourth 24 h following surgery. The mental ability of
each patient, as we have already mentioned, was evalu-
ated using the Hasegawa score, having the lowest and
highest score recorded as 0 and 38 respectively and a
mean value of 27.95  11. 38. According to the results
of our study, we have created the following algorithm:
3.738  sample 3  4.221  sample 2  6.767
If the above equation is fulfilled there is a very high pos-
sibility for postoperative brain dysfunction.
Statistical analysis
The normality assumption of the Hasegawa score 
distribution was tested with the use of the Kolmogorof–
Smirnof test. Various nonparametric tests such as Mann-
Whitney U-test, and Friedman’s test were used, depending
on the number of distributions tested. All the tests were
at the level of significance a 	 0.05. The p-value of the
Kolmogorof–Smirnof test is p 	 0.000 which rejects
the null hypothesis of Normality of the Hasegawa score.
Using the above Hasegawa dementia scale, patients’
population has been classified into four categories
according to their mental stage (Table 1).
Friedman’s test has been used for the testing of the
equality of the distributions of the four NSE measure-
ments. The power of the test is p 	 0.000, which means
that the four distributions are not the same. The power
of the Friedman test for the four NSE measurements
within each of the four categories A, B, C, D, are 0.00,
0.00, 0.034, 0.37 respectively (Tables 2 and 3). It
becomes obvious that the more severe the brain damage
the stronger we reject the equality of the distributions.
For the category D, where no brain dysfunction noted,
the equality of the four distributions can not be
rejected. Mean Hasegawa score for men and women 
is 25.61  7.61 and 32.12  6.8 respectively. The 
p-value for the U-test is p 	 0.012. The latter means
that female patients take systematically higher score
compared to the male ones. Spearman correlation coef-
ficients between the age and the four NSE measure-
ments were low, between 0.26 and 0.29. In terms of the
type of surgery, it was mentioned that the patients
under general surgery developed almost no brain dys-
function. It has been observed that 75% of the patients
under general surgery did not develop any brain dam-
age. A percentage of 25% of them are at the limited
stage (C).
Then, we have grouped the four categories into two
groups. The first group (group I) includes the categories
A, B, C, in which the patients have developed brain dys-
function, while the second group (group II) includes the
category D, i.e. the patients who did not develop any
type of brain dysfunction. The statistical features of the
two groups are summarised in Table 4. It is obvious at
the above table that the mean NSE level is the same in
all four samples. The summary of the logistic regression
is also presented in Table 5. The p-value of the Friedman’s
test is p 	 0.31, which does not reject the equality of
the distributions. The same does not hold for Group B
of the sick patients. The same test rejects the equality 
of the distributions of the four NSE measurements
(p 	 0.000) (Fig. 1).
Table 1. Categories of patients according to Hasegawa score
Category Hasegawa score Mental stage Sample 1 Sample 2 Sample 3 Sample 4
A 0–10 Dementia 9.06  2.87 10.25  3.13 17.94  5.37 17.15  7.15
B 10.5–21.5 Partial dementia 8.14  2.7 9.38  2.62 15.7  4.38 16.36  6.17
C 22–30.5 Limited 5.62  1.64 7.16  3.87 9.36  5.06 8.26  5.11
D 
31 Normal 9.16  4.74 9.54  4.72 9.19  4.26 9.20  4.02
Mean 27.9  11.8 8.7  4.2 9.4  4.3 11.05  5.5 10.9  5.8
Table 2. Distribution of the patient’s four categories in
terms of the two types of surgery
Category General surgery Cardiac surgery Total
A 0 (25%) 12 (24%) 12 (13.1%)
B 0 (25%) 10 (20%) 10 (10.8%)
C 21 (25%) 3 (6%) 24 (26.1%)
D 21 (25%) 25 (50%) 46 (50%)
Total 42 (45.6%) 50 (54.4%) 92 (100%)
Table 3. Statistical features of the four NSE samples in
terms of the kind of surgery
General surgery Cardiac surgery Total
Sample 1 8.66  5.44 8.83  2.09 8.7  4.2
Sample 2 8.77  5.50 9.95  2.90 9.4  4.3
Sample 3 7.77  4.46 13.81  4.85 11.05  5.5
Sample 4 8.09  4.56 13.33  5.71 10.9  5.8
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In a graphic representation of this prognostic model
(Fig. 2), patients at risk to develop brain ischaemia dur-
ing cardiac surgery are distributed in the area above the
line, while patients distributed in the area below the line
are in significantly less risk to develop postoperative
brain dysfunction. An attempt has been also made to
construct a more convenient model by replacing the
NSE levels by the time of stress period; however the
result of this attempt was rather poor as the percentage
of correct prediction was only 50% and consequently,
it was abandoned.
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Figure 1. Mean values  sd for the four levels of NSE in the
two group of patients.
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Figure 2. Geometric interpretation of the logistic model.
Table 4. Statistical features of the group of patients who have (group I) and have not
(group II) developed postoperative brain dysfunction
Hasegawa score Sample 1 Sample 2 Sample 3 Sample 4
Group I 14.6  11.3 7.2  2.8 9.1  3.3 14.9  5.9 14.5  7.2
Group II 34.3  1.6 9.1  4.7 9.5  4.7 9.1  4.2 9.2  4.0
Table 5. Summary of the logistic regression
Predicted values
Group A Group B Percentage of
(dementia) (healthy) correct prediction
Recorded values
Group A (dementia) 24 1 96%
Group B (healthy) 1 24 96%
Percentage of correct prediction 96% 96% 96%
DISCUSSION
The aim of our study was to correlate the NSE blood
serum levels during and immediately after surgery with
the incidence of the postoperative brain damage, in
patients undergoing general and open-heart surgery.
Our hypothesis was that NSE is released as a result of
brain tissue destruction.
There are previously published studies proposing the
detection of the NSE isoenzyme in CSF, as the preferable
method in terms of diagnostic accuracy. However, there
are several limitations regarding the use of this method.
A number of technical problems, such as the patient
position or the multiple punctures of the dura mater nec-
essary to obtain a series of samples in different times,
make an attempt to take CSF samples during the opera-
tion difficult or even impossible. Thus, all the available
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published series using the above method, detect the NSE
levels in CSF after the end of the operation; however, in
this situation, the most crucial samples during the oper-
ation are lost. Alternatively, some authors recommend
the detection of the NSE levels in blood serum as an
accurate and effective method for the prognosis of the
postoperative brain dysfunction [Roine et al, 1989].
A review of the published literature reveals a signifi-
cant variance in the conclusions concerning the rela-
tionship between the NSE levels and the postoperative
brain dysfunction.
Johnsson et al [1995, 1996] found high NSE levels in
cardiosurgical patients but not critical neurological out-
come in the postoperative period. Sellman et al [1992]
found no relationship between high NSE levels 
and postoperative brain damage. Isgro et al [1997], 
suggested that high NSE levels after open-heart surgery
are followed by brain damage installation and
Hardemark et al in 1988 and 1989, found a quantita-
tive relationship between the NSE levels and the sever-
ity of the postoperative brain damage [Hardemark et al,
1988, 1989].
According to older studies [Frank et al, 1972] the inci-
dence of the postoperative neurological complications
following cardiac surgery can be described by a 0–100%
scale. In most recent publications, Adrian et al [1995],
found neurological complications ranging from 1 to
57%. In our study, the incidence of neurological compli-
cations was 44% for the open-heart surgery group and
not significant for the general surgery group. The serum
NSE levels among the four different blood samples were
found the same in the general surgery group, but this was
not the case in the open-heart surgery group (p-values:
0.612 and 0.000, median Hasegawa score: 33.6  2.72
and 23.14  13.51 respectively).
The current trend regarding open-heart procedures,
is towards early mobilisation and shorter hospitalisa-
tion, especially concerning the postoperative period
patients spend in the ICU. In the presented study, we
have collected three different blood samples for each
individual patient during the operation, as we have
assessed this period as the most crucial in the prognosis
of postoperative brain dysfunction. To further support
this assessment, the highest NSE serum levels have been
found during the ECC. Thus, by evaluating the NSE
levels at the time 2 and 3 of the operation, it may be
possible to identify the patients in high-risk for post-
operative brain damage.
Savageau et al [1982], identified a positive relation
between patient’s age and postoperative brain damage.
We have also found a similar correlation between these
two parameters. Furthermore, sex was found another
factor influencing brain dysfunction following cardiac
surgery. Men in our study had a median Hasegawa score
of 25.61  7.61, while the mean Hasegawa score for
women was 32.12  6. NSE serum levels at the same time
were lower for female than for male patients. These results
indicate that women are expected to have better neuro-
logical outcome in the postoperative period, but this can-
not be an absolute conclusion since the number of female
patients in the open-heart surgery group was small.
Another relationship was also found between the dura-
tion of the ECC and the installation of postoperative
brain dysfunction in our series. It is obvious that when
the time of the ECC is prolonged, the possibility for the
occurrence of events that may influence brain function
becomes higher and this must be the most probable expla-
nation for this correlation. Similar results and conclusions
have been also presented in other published studies
[Isgro et al, 1997; Sellman et al, 1992].
A number of previously reported series [Aberg et al,
1984; Sellman et al, 1992; Zelter et al, 1986], have
examined the role of various other enzymes as indica-
tors of the postoperative brain dysfunction is an intra-
cellular enzyme that can be detected in the red blood
cells as well as in CSF after cerebral ischaemia. The
detection of high levels of AK has a positive correlation
to brain dysfunction after ECC but the presence of AK
in serum may be also the result of haemolysis and thus,
a cause of false positive results. The detection of protein
S1002 [Sellman, 1992] may also be used as an indicator
of the postoperative brain damage, but it is a more
expensive and a less sensitive method. CK-BB [Taylor 
et al, 1980] is a predictive biochemical marker used 
by some investigators, but has not proved as reliable 
as NSE as it creates frequent cross-reactions to other
isoenzymes. Eventually, it seems that the detection of
blood serum NSE is the most accurate and reliable factor
available for early prognosis of brain dysfunction fol-
lowing open-heart surgery [Johnsson et al, 1996].
CONCLUSION
The results of our double blind study shows that blood
serum NSE levels, particularly immediately before and
after the ECC, is a sensitive, inexpensive and safe method
that may contribute significantly in the early prognosis of
postoperative brain dysfunction. Further studies focusing
on the predictive role of the NSE levels in different types
of operations with a high incidence of perioperative brain
ischaemia, such as thoracic aorta or brain aneurysms,
will be necessary for evaluation of its efficacy as a prog-
nostic factor in a wider range of performances.
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